Screener
Taysha Gene Therapies, Inc. TSHA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
FAQ
- What is Taysha Gene Therapies, Inc.'s retained earnings?
- Taysha Gene Therapies, Inc. (TSHA) reported retained earnings of -$800.35M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s retained earnings changed year-over-year?
- Taysha Gene Therapies, Inc.'s retained earnings decreased by 23.0% year-over-year, from -$650.72M to -$800.35M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s retained earnings has grown at a 63.4% compound annual growth rate (CAGR), from -$61.13M to -$711.3M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Taysha Gene Therapies, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude